Informational letter to healthcare professionals regarding the risk of anaphylactic reactions several months or years after the start of treatment with glatiramer acetate (COPAXONE®-TEVA, COPAXONE 40).

31.12.2024 997 views

Інформаційний лист-звернення до спеціалістів системи охорони здоров’я щодо ризику виникнення анафілактичних реакцій через кілька місяців або років після початку лікування глатирамеру ацетатом (КОПАКСОН®-ТЕВА, КОПАКСОН 40).PDF · 193 КБ

Завантажити

Informational letter to healthcare professionals regarding the risk of anaphylactic reactions several months or years after the start of treatment with glatiramer acetate (COPAXONE®-TEVA, COPAXONE 40).

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Informational letter to healthcare professionals regarding the risk of anaphylactic reactions several months or years after the start of treatment with glatiramer acetate (COPAXONE®-TEVA, COPAXONE 40).

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration